Unicycive Therapeutics, Inc. Balance Sheet
UNCY|3 years of annual SEC 10-K data (FY2022-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Unicycive Therapeutics, Inc. had $32M in total assets with negative shareholders' equity of $4M as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Cash & Equivalents | - | - | $455.0K |
| Inventory | - | - | $2.2M |
| Current Assets | $30.9M | $13.4M | $2.6M |
| PP&E (Net) | $75.0K | $26.0K | $22.0K |
| Total Assets | $31.7M | $14.2M | $2.8M |
| Current Liabilities | $24.1M | $17.5M | $3.3M |
| Shareholders' Equity | -$3.8M | -$466.0K | $16.5M |